The Safety of Local Hormonal Treatment for Vulvovaginal Atrophy in Women With Estrogen Receptor-Positive Breast Cancer on Adjuvant Aromatase Inhibitor Therapy: Meta-Analysis
August 2019
in “
Clinical breast cancer
”
local hormonal treatment vulvovaginal atrophy estrogen receptor-positive breast cancer adjuvant aromatase inhibitor therapy luteinizing hormone estradiol sex hormone binding globulins follicle stimulating hormone vaginal estrogen vaginal discharge facial hair growth urinary tract infections yeast infections vaginal itching vulvar itching local hormone therapy facial hair UTIs
Studysummary This meta-analysis found that in postmenopausal women with a history of breast cancer, 8 weeks of vaginal estrogen therapy while on aromatase inhibitors did not result in systemic absorption of sex hormones, suggesting potential safety for treating vulvovaginal atrophy in this context.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on clinical-breast-cancer.com →